Figure 2.

R-59-022 inhibits EBOV GP-mediated entry in bone marrow-derived macrophages. BMDMs were pre-treated for 1 hour with increasing concentrations of R-59-022 or vehicle and exposed to βlam VLPs harbouring EBOV GP or VSV G. Infection was measured by determining the percentage of cells with cytoplasmic βlam by CCF2-AM staining and flow cytometry analysis. Data are expressed as percentages relative to vehicle-treated cells. Metabolic activity was measured in parallel and was also normalized to vehicle-treated cells. Data are representative of 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001.